Joining VeloClub not only supports the work we do, there are some fantastic benefits:
by Mark Zalewski
March 23, 2017
In today’s CyclingTips Daily News Digest: Strength in numbers: Quick-Step goes 1-2 from breakaway at Dwars Door Vlaanderen; Lotta Lepistö wins Dwars door Vlaanderen; Valverde wins in Catalunya, Van Garderen into lead; Movistar team responds to Catalunya TTT relegation; Team Wiggins left out of Tour de Yorkshire; Lars Boom ‘In Astana I lacked the necessary support’; Reijnen comes away with a few stitches after crashing into ditch at Dwars door Vlaanderen; British amateur cyclist suspended two years for doping positive; Cylance men’s team to race entirely on disc brakes; Trofeo Alfredo Binda highlights; Kenny Belaey rides the UCI HQ; Video: Flanders Classics 2016 compilation.
A 55-year-old British amateur cyclist has been suspended for two years following an Anti-Doping Rule Violation (ADRV). Michael Ellerton, who was previously registered with Team Swift, tested positive for the glucocorticoids prednisone and prednisolone, following an in-competition test at the Port Talbot Wheelers Cycling Club’s annual 25 Mile Time Trial on 11 September 2016.
Ellerton claimed the positive test was a result of taking medication for mouth ulcers in the lead up to the race. He retroactively applied to UKAD for a Therapeutic Use Exemption (TUE) but the application was rejected by the TUE Committee.
“UKAD is satisfied that Ellerton did not act intentionally, according to the Anti-Doping Rules, and that the prohibited substances were used out-of-competition in a context unrelated to sport performance,” a statement said. “As a result, a two-year period of ineligibility has been imposed.”
“The World Anti-Doping Code is based on the principle of strict liability,” UKAD Director of Operations, Pat Myhill said. “Every athlete, no matter what level, is solely responsible for any prohibited substance which is found in their system, regardless of how it got there or whether there was an intention to cheat or not.
Click through to read more at UKAD.